Relation and Deerfield form NewCos to develop drugs from AI-discovered targets

Relation, a technology-enabled biopharmaceutical company, announced a strategic research collaboration with healthcare investment firm Deerfield Management to advance therapeutic discovery projects for diseases with high unmet need.1 2

Relation will use its AI-driven 'Lab-in-the-Loop' platform, which integrates patient-derived multi-omic data and proprietary experimental systems, to uncover causal genes and refine drug target hypotheses.1 2

Under the agreement, Relation may nominate targets discovered on its platform for downstream development through a jointly owned NewCo (new company) structure with Deerfield.1 2

Both parties will collaborate to develop target product profiles for selected programs, with Deerfield providing due diligence support and drug development plans for mutually agreed projects.1 2

Relation and Deerfield will each be entitled to royalties on net sales of any future products arising from the collaboration.1 2

The collaboration focuses on building a pipeline of novel therapeutics across therapy areas including immunology, metabolic disease, and bone disease, leveraging improved understanding of disease biology.1 2

Deerfield’s internal drug discovery and development engine, Deerfield Discovery and Development (3DC), is involved via its VP of Genetics and Genomics, highlighting an emphasis on genetics- and biology-informed target selection.1 2

Sources:

1. https://www.globenewswire.com/news-release/2026/01/07/3214282/0/en/Relation-Announces-Strategic-Collaboration-with-Deerfield-Management-to-Advance-Novel-Therapeutics.html

2. https://smb.bgdailynews.com/article/Relation-Announces-Strategic-Collaboration-with-Deerfield-Management-to-Advance-Novel-Therapeutics?storyId=695e135aeb1c137304e2230f

Sources:

Leave a Reply Cancel reply